← Human Trials & Peer-Reviewed Studies
[Effect of recombinant human growth hormone on postoperative fatigue syndrome in patients after cardiac operations].
Plain-language guide to PMID 12126548 (2002): double-blind randomized controlled trial of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 60 patients.
Key Facts
- PMID
- 12126548
- Journal
- Zhonghua yi xue za zhi
- Year
- 2002
- Study type
- Randomized Controlled Trial
- Authors
- Mao Z et al. (3 authors)
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over), published as a randomized controlled trial.
To observe the effect of recombinant human growth hormone (rhGH) treatment on postoperative fatigue syndrome (POFS) in patients after cardiac surgery under cardiaopulmonary bypass (CPB).
Who Took Part
According to the abstract, 60 patients were involved.
By PubMed's age tags, the people studied were teenagers, adults, middle-aged adults and older adults, both men and women.
The patients were asked to score their sense of fatigue (Christensen scores).
How the Study Was Run
In design terms this was a randomized, double-blind and placebo-controlled study.
Random assignment meant chance, not the researchers, decided who got Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and who got the comparison, which limits bias.
Blinding on both sides kept the patients and researchers unaware of who received Exogenous HGH, sermorelin & older GHRPs (why they're passed over).
The comparison arm used a placebo, so changes seen with Exogenous HGH, sermorelin & older GHRPs (why they're passed over) could be set against what happens without it.
The serum growth hormone (GH) and plasma proteins were detected.
What Was Measured
Topics PubMed links to this paper include Blood Proteins, Cardiopulmonary Bypass, Fatigue, Growth Hormone, Postoperative Complications, Prealbumin and Transferrin.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 60 patients.
Its findings take up roughly 9 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.
The publication is from 2002 (Zhonghua yi xue za zhi), a journal based in China.
More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.
Our Notes on the Compound
Exogenous HGH, sermorelin & older GHRPs (why they're passed over): Constant levels suppress the body's own GHRH, raise somatostatin and dull pituitary response.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.